drugset / Trial / NCT07822373
A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether Enfortumab Vedotin in combination with Pembrolizumab can achieve a clinical response that preserves the bladder and avoids the need for cystectomy or radiation therapy in patients with urothelial cancer.
Timeline
- Start
- 2026-11
- Primary completion
- 2034-11
- Completion
- 2035-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfortumab Vedotin | Other / unclassified | 1.25 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Background | berahyaluronidase alfa-pmph | Unknown | — | Subcutaneous |